WO2012102521A3 - 인간 항-ＣＤ23 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물 - Google Patents

인간 항-ＣＤ23 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물 Download PDF

Info

Publication number
WO2012102521A3
WO2012102521A3 PCT/KR2012/000521 KR2012000521W WO2012102521A3 WO 2012102521 A3 WO2012102521 A3 WO 2012102521A3 KR 2012000521 W KR2012000521 W KR 2012000521W WO 2012102521 A3 WO2012102521 A3 WO 2012102521A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
fab antibody
same
human anti
treating tumours
Prior art date
Application number
PCT/KR2012/000521
Other languages
English (en)
French (fr)
Other versions
WO2012102521A2 (ko
Inventor
차상훈
Original Assignee
주식회사 아이지세라피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 아이지세라피 filed Critical 주식회사 아이지세라피
Publication of WO2012102521A2 publication Critical patent/WO2012102521A2/ko
Publication of WO2012102521A3 publication Critical patent/WO2012102521A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명은 IM-9 세포 표면에 발현하는 CD23에 특이적으로 결합하는 Fab 항체 및 이를 포함하는 종양 치료용 약학조성물에 관한 것으로, 본 발명에 따른 항-CD23 인간 Fab 항체를 이용하면, CD23에 대한 특이성이 높아서, 종양 치료용 약학 조성물 및 백혈병 치료용 약학조성물을 제공할 수 있다.
PCT/KR2012/000521 2011-01-27 2012-01-20 인간 항-ＣＤ23 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물 WO2012102521A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0008403 2011-01-27
KR1020110008403A KR20120092767A (ko) 2011-01-27 2011-01-27 인간 항-ＣＤ23 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물

Publications (2)

Publication Number Publication Date
WO2012102521A2 WO2012102521A2 (ko) 2012-08-02
WO2012102521A3 true WO2012102521A3 (ko) 2012-11-29

Family

ID=46581261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/000521 WO2012102521A2 (ko) 2011-01-27 2012-01-20 인간 항-ＣＤ23 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물

Country Status (2)

Country Link
KR (1) KR20120092767A (ko)
WO (1) WO2012102521A2 (ko)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BONNEFOY, J. Y. ET AL.: "Production and characterization of a monoclonal anti body specific for the human lymphocyte low affinity receptor for IgE: CD23 is a low affinity receptor for IgE", JOURNAL OF IMMUNOLOGY., vol. 138, no. 9, 1 May 1987 (1987-05-01), pages 1970 - 1978 *
CHOI, H. J. ET AL.: "Isolation of human Fab antibodies specific for the low-affmity IgE receptor (CD23) by selecting a hierarchical antibody library system against B lymphoblastic IM-9 cells", IMMUNOLOGY LETTERS., vol. 136, no. 2, 26 January 2011 (2011-01-26), pages 213 - 220, XP028370309, DOI: doi:10.1016/j.imlet.2011.01.012 *
FLORES-ROMO, L. ET AL.: "Inhibition of an in vivo antigen-specific IgE response by antibodies to CD23", SCIENCE., vol. 261, no. 5124, 20 August 1993 (1993-08-20), pages 1038 - 1041, XP002137882, DOI: doi:10.1126/science.8351517 *
KAWABE, T. ET AL.: "Regulation of Fc epsilon R2/CD23 gene expression by cytokines and specific ligands(IgE and anti-Fc epsilonR2 monoclonal antibody). Variable regulation depending on the cell types", JOURNAL OF IMMUNOLOGY, vol. 141, no. 4, 15 August 1988 (1988-08-15), pages 1376 - 1382 *
POOLE, J. A. ET AL.: "Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen- induced responses in antigen-presenting cells and T cells from atopic subjects", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY., vol. 116, no. 4, pages 780 - 788, XP005094469, DOI: doi:10.1016/j.jaci.2005.07.007 *

Also Published As

Publication number Publication date
WO2012102521A2 (ko) 2012-08-02
KR20120092767A (ko) 2012-08-22

Similar Documents

Publication Publication Date Title
TN2014000134A1 (en) Therapeutic peptides
HK1202557A1 (en) Antibodies against claudin 18.2 useful in cancer diagnosis 18.2
IL252154A0 (en) Antibodies against dr5, preparations containing them and their uses
IL229098A0 (en) Antibodies against CD-40, preparations containing them and their uses
WO2012100097A3 (en) Topical minocycline compositions and methods of using the same
IL229061B (en) Antibody against 3h – 7b, polynucleotides encoding it, preparations containing it and its uses
WO2013096291A3 (en) Modified polypeptides for bispecific antibody scaffolds
WO2013006490A3 (en) Antibodies that specifically bind to tim3
WO2014144791A3 (en) Therapeutic peptides
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
IL228715A0 (en) Aminopyrazine compounds, preparations containing them and their uses
WO2012018903A3 (en) Intersecting plate shaped abrasive particles
PH12014502406B1 (en) Anti-il-23p19 antibodies
IL227682A0 (en) Compounds suppressing 17-il and γ- ifn, preparations containing them and their uses
SI2739615T1 (sl) Fenil-3-aza-biciklo(3.1.0)heks-3-il-metanoni in njihova uporaba kot zdravilo
WO2014080286A3 (en) Methods and compositions for treating multiple sclerosis and related disorders
NZ749998A (en) Tfpi inhibitors and methods of use
NZ717192A (en) Anti-inflammatory tripeptides
WO2013064388A3 (de) Kosmetische formulierung enthaltend n-acyl - phytosphingosin
WO2013081420A3 (ko) 페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물
WO2012138653A3 (en) Treatment regimens
WO2012102521A3 (ko) 인간 항-ＣＤ23 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물
WO2012174280A3 (en) Methods and compositions for modulating myofibroblast activities
WO2013003547A3 (en) Bhq-conjugates, and related compounds, methods of making the same, and methods of use thereof
PH12015502015B1 (en) Coated phenylephrine particles and use thereof in pharmaceutical formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12738746

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12738746

Country of ref document: EP

Kind code of ref document: A2